Literature DB >> 9006662

Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions.

H K Wolf1, S Normann, A J Green, I von Bakel, I Blümcke, T Pietsch, O D Wiestler, A von Deimling.   

Abstract

Glioneuronal malformations with a striking histological resemblance to cortical tubers of tuberous sclerosis, but no extracerebral stigmata of this phacomatosis, are frequently encountered in patients with chronic pharmacoresistant epilepsies. It is controversial as to whether these lesion represent a forme fruste of tuberous sclerosis or a distinct entity. The recently reported loss of heterozygosity (LOH) at the regions of the TSC1 or TSC2 locus in hamartomas obtained from different organs of patients with established tuberous sclerosis, including cortical tubers, stimulated us to examine epilepsy-associated tuberous sclerosis-like glioneuronal malformations with respect to LOH at the TSC1 and TSC2 loci of chromosomes 9q34 and 16p 13.3, respectively. The analysis was carried out on DNA derived from paraffin-embedded brain tissues of 11 patients. For 5 patients, peripheral blood leukocytes were also available for DNA extraction. We performed microsatellite analysis with five markers on chromosome 9 and four markers on chromosome 16. In addition, polymerase chain reaction-restriction fragment length polymorphism (RFLP) analysis was performed using a polymorphic EcoRV restriction site in exon 40 of the TSC2 gene. No LOH was identified in any of the cases. These findings do not support a relationship between the epilepsy-associated glioneuronal lesions and tuberous sclerosis. However, tuberous sclerosis is genetically heterogeneous and microsatellite and RFLP analysis cannot exclude small deletions or point mutations. Thus, given the histopathological similarity of glioneuronal malformations in epilepsy patients to cortical tubers, further molecular genetic studies will be needed as our understanding of the molecular basis of tuberous sclerosis increases to completely clarify the relationship of these lesions to tuberous sclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006662     DOI: 10.1007/s004010050587

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  7 in total

1.  Biallelic TSC gene inactivation in tuberous sclerosis complex.

Authors:  Peter B Crino; Eleonora Aronica; Gordon Baltuch; Katherine L Nathanson
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

Review 2.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

3.  The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes.

Authors:  Jerzy Wegiel; Izabela Kuchna; Krzysztof Nowicki; Humi Imaki; Jarek Wegiel; Elaine Marchi; Shuang Yong Ma; Abha Chauhan; Ved Chauhan; Teresa Wierzba Bobrowicz; Mony de Leon; Leslie A Saint Louis; Ira L Cohen; Eric London; W Ted Brown; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2010-03-03       Impact factor: 17.088

Review 4.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2006-08-09       Impact factor: 4.231

5.  Monoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.

Authors:  Karolina Pilipow; Veronica Basso; Nicola Migone; Anna Mondino
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

Review 6.  Mechanistic target of rapamycin signaling in human nervous system development and disease.

Authors:  Marie Girodengo; Sila K Ultanir; Joseph M Bateman
Journal:  Front Mol Neurosci       Date:  2022-09-26       Impact factor: 6.261

Review 7.  Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.

Authors:  Masashi Mizuguchi; Maki Ohsawa; Hirofumi Kashii; Atsushi Sato
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.